Canada markets open in 1 hour 6 minutes

POINT Biopharma Global Inc. (PNT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
8.68+0.45 (+5.47%)
At close: 04:00PM EDT
8.68 0.00 (0.00%)
Pre-Market: 08:12AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close8.23
Open8.14
Bid6.89 x 1000
Ask12.50 x 1000
Day's Range8.10 - 8.81
52 Week Range4.25 - 11.72
Volume463,281
Avg. Volume661,503
Market Cap782.285M
Beta (5Y Monthly)0.07
PE Ratio (TTM)N/A
EPS (TTM)-0.69
Earnings DateNov 10, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.25
  • GlobeNewswire

    POINT Biopharma to Publish Abstract at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial

    In advance of the abstract publication, POINT hosted an educational webinar entitled “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm” Watch the replay at https://hub.pointbiopharma.com/controlarm INDIANAPOLIS, Aug. 18, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the company will be publishing an abstract at ESMO

  • GlobeNewswire

    POINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business Highlights

    Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha targeted program, enters Phase 1 clinical trial INDIANAPOLIS, Aug. 12, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the second quarter

  • GlobeNewswire

    POINT Biopharma to Host Investor Education Event, “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”, on August 18, 2022

    The event will prepare investors for the release of SPLASH’s lead-in cohort efficacy data later this year by providing an overview of SPLASH’s trial design. Register online today at https://hub.pointbiopharma.com/controlarm INDIANAPOLIS, Aug. 08, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, announced that next week, on Thursday, August 18, 2